HK1054192B - New formula of KAHALALIDE F - Google Patents

New formula of KAHALALIDE F Download PDF

Info

Publication number
HK1054192B
HK1054192B HK03106441.9A HK03106441A HK1054192B HK 1054192 B HK1054192 B HK 1054192B HK 03106441 A HK03106441 A HK 03106441A HK 1054192 B HK1054192 B HK 1054192B
Authority
HK
Hong Kong
Prior art keywords
kahalalide
cancer
infusion
formulation
reconstituted
Prior art date
Application number
HK03106441.9A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1054192A1 (en
Inventor
Glynn Thomas Faircloth
Bastian Nuyen
Steve Weitman
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of HK1054192A1 publication Critical patent/HK1054192A1/en
Publication of HK1054192B publication Critical patent/HK1054192B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK03106441.9A 2000-10-31 2001-10-31 New formula of KAHALALIDE F HK1054192B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US60/244,471 2000-10-31
US24622900P 2000-11-06 2000-11-06
US60/246,229 2000-11-06
US34844901P 2001-10-19 2001-10-19
US60/348,449 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en) 2000-10-31 2001-10-31 Kahalalide f formulation

Publications (2)

Publication Number Publication Date
HK1054192A1 HK1054192A1 (en) 2003-11-21
HK1054192B true HK1054192B (en) 2006-09-08

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106441.9A HK1054192B (en) 2000-10-31 2001-10-31 New formula of KAHALALIDE F

Country Status (22)

Country Link
US (1) US7473681B2 (https=)
EP (1) EP1330258B1 (https=)
JP (2) JP2004512370A (https=)
KR (1) KR100834138B1 (https=)
CN (1) CN1568192A (https=)
AT (1) ATE314084T1 (https=)
AU (2) AU1074902A (https=)
BR (1) BR0114912A (https=)
CA (1) CA2425627A1 (https=)
CY (1) CY1105009T1 (https=)
CZ (1) CZ20031211A3 (https=)
DE (1) DE60116359T2 (https=)
DK (1) DK1330258T3 (https=)
ES (1) ES2256305T3 (https=)
HK (1) HK1054192B (https=)
HU (1) HUP0600031A3 (https=)
IL (2) IL155297A0 (https=)
MX (1) MXPA03003704A (https=)
NO (1) NO331082B1 (https=)
NZ (1) NZ525243A (https=)
SK (1) SK286421B6 (https=)
WO (1) WO2002036145A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
DK1572726T3 (da) * 2002-10-18 2011-03-28 Pharma Mar Sau 4-methylhexansyre-kahalalid F-forbindelse
NZ539093A (en) * 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
DE69719265T2 (de) 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
CN1322136A (zh) 1998-09-23 2001-11-14 马库斯·基普 用于选择性神经元辐射防护的神经亲免素类物质
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
EP1330258B1 (en) 2005-12-28
AU2002210749B2 (en) 2006-12-21
CN1568192A (zh) 2005-01-19
HUP0600031A3 (en) 2012-02-28
DE60116359D1 (de) 2006-02-02
JP2004512370A (ja) 2004-04-22
CZ20031211A3 (cs) 2003-09-17
KR20030044005A (ko) 2003-06-02
IL155297A0 (en) 2003-11-23
JP2010047601A (ja) 2010-03-04
PL360848A1 (en) 2004-09-20
MXPA03003704A (es) 2004-05-04
ATE314084T1 (de) 2006-01-15
US7473681B2 (en) 2009-01-06
CY1105009T1 (el) 2010-03-03
DE60116359T2 (de) 2006-09-28
AU1074902A (en) 2002-05-15
HK1054192A1 (en) 2003-11-21
SK5022003A3 (en) 2003-12-02
BR0114912A (pt) 2003-10-14
WO2002036145A2 (en) 2002-05-10
NO331082B1 (no) 2011-10-03
NZ525243A (en) 2005-01-28
KR100834138B1 (ko) 2008-06-02
WO2002036145A3 (en) 2002-10-17
CA2425627A1 (en) 2002-05-10
SK286421B6 (sk) 2008-09-05
DK1330258T3 (da) 2006-05-22
NO20031860D0 (no) 2003-04-25
US20040067895A1 (en) 2004-04-08
IL155297A (en) 2010-05-31
ES2256305T3 (es) 2006-07-16
HUP0600031A2 (en) 2006-05-29
EP1330258A2 (en) 2003-07-30
WO2002036145A8 (en) 2003-10-23
NO20031860L (no) 2003-06-30

Similar Documents

Publication Publication Date Title
EP1330258B1 (en) Kahalalide f formulation
AU2002210749A1 (en) Kahalalide F formulation
JP2004512370A5 (https=)
RU2620341C2 (ru) Стабилизированная композиция пеметрекседа
KR102430891B1 (ko) 응집체-비함유 단량체성 디프테리아 독소 융합 단백질의 제조 방법 및 치료적 용도
TW201632174A (zh) 使用晶體工程及茶胺酸溶解之平台藥物遞送系統
ES2740953T3 (es) Bloqueo de proteasas inflamatorias con theta-defensinas
DE69434244T2 (de) Verbesserte krebstherapie
WO2021203467A1 (zh) 一类脂肽化合物在抗新型冠状病毒中的应用
KR20230133475A (ko) 화학유전학적으로 활성화 가능한 팔미토일화 조절 단백질 및 이의 용도
US20050054555A1 (en) Kahalalide compounds for use in cancer therapy
RU2292216C2 (ru) Кахалалид f
AU2002334203B2 (en) Kahalalide compounds for use in cancer therapy
AU2002334203A1 (en) Kahalalide compounds for use in cancer therapy
JP2017506665A (ja) 細胞アシドーシスの操作のためのニトロベンズアルデヒドプロトン放出方法
US20230201168A1 (en) New therapy for the treatment of tumors
TWI754828B (zh) Ogg1的粉末化組成物及其用途
CN118632705A (zh) 用于预防或减少有机磷酸酯和其他有毒材料的毒性的材料和方法
JP6041811B2 (ja) 細菌由来の感染症を治療する抗細菌剤
PL203676B1 (pl) Liofilizowany preparat kahalalidu F, zestaw, odtworzony roztwór i zastosowanie
AU2020298031A1 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
US20250041234A1 (en) Use of thermostable exoshells for lyophilization of labile substrates
WO2023196891A2 (en) Methods of treating cancer by inhibiting bacterial dnak to restore activities of anticancer drugs
KR20210101193A (ko) 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제
JP2007191417A (ja) 医薬用の組成物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111031